GLAXF News and Press, GlaxoSmithKline Plc From 01/03/23

Summary My portfolio, built specifically for my retirement ~20+ years from now gets a nice end-of-the-year Petrobras dividend to help ease market pain. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping creat...

Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...

Summary IQDG is a large-cap, ex-US dividend growth ETF. 79% of asset value is in European companies. It is well-balanced across sectors, but quite concentrated in the top holdings. Past performance is underwhelming relative to its peers. IQDG's strategy and portfolio...

Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...

Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore fu...

Summary British pharmaceutical company GSK has seen an 8% price rise since I wrote about it a little over a month ago. What has driven this? Its upgraded earnings outlook and approvals for its treatments have likely buoyed the stock, adding to the already improving market mood. ...

Summary Fisher’s 13F portfolio value decreased from ~$141B to ~$133B in Q3 2022. They added Charles Schwab and increased Nvidia, Morgan Stanley, and Goldman Sachs while decreasing Salesforce, Visa, Alibaba Group Holdings, Novartis, Verizon, and Tencent Holdings. The top...

Summary AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintainin...

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...

GSK plc (GSK) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Debo...